跳轉至內容
Merck
全部照片(1)

Key Documents

View All Documentation

B1532

Sigma-Aldrich

Resorufin benzyl ether

CYP450 substrate, ≥98% (TLC), powder

同義詞:

7-Benzyloxy-3H-phenoxazin-3-one, 7-Benzyloxyresorufin, O7-Benzylresorufin

登入查看組織和合約定價
全部照片(1)

About This Item

經驗公式（希爾表示法）:
C19H13NO3
CAS號碼:
87687-02-3
分子量：:
303.31
MDL號碼:
MFCD00171613
分類程式碼代碼:
12352204
PubChem物質ID:
24891597
NACRES:
NA.32

product name

Resorufin benzyl ether, CYP450 substrate

品質等級

200

化驗

≥98% (TLC)

形狀

powder

溶解度

chloroform: 9.80-10.20 mg/mL, clear, orange

儲存溫度

2-8°C

SMILES 字串

O=C1C=CC2=Nc3ccc(OCc4ccccc4)cc3OC2=C1

InChI

1S/C19H13NO3/c21-14-6-8-16-18(10-14)23-19-11-15(7-9-17(19)20-16)22-12-13-4-2-1-3-5-13/h1-11H,12H2

InChI 密鑰

XNZRYTITWLGTJS-UHFFFAOYSA-N

基底

Fluorimetric substrate for cytochrome P450-linked enzymes.

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H315,H319,H335

危險分類

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 1

1 of 1

普罗地芬 盐酸盐 analytical standard, ≥95%

Supelco

P1061

普罗地芬 盐酸盐

Shosaku Kashiwada et al.
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP, 141(4), 338-348 (2005-08-23)
Phylogenic analysis of the teleost genomic lineages has demonstrated the precedent for multiple genome duplications. Among many of the genes duplicated, cytochrome P450 genes have undergone independent diversification, which can be traced to a single ancestral gene. In teleosts, cytochrome
R W Nims et al.
The Journal of pharmacology and experimental therapeutics, 270(1), 348-355 (1994-07-01)
To explore further the structural requirements for ligand interaction with the putative phenobarbital receptor, the pharmacodynamics of CYP2B induction by 5,5-diphenylbarbituric acid, phenytoin (5,5-diphenylhydantoin), barbital (5,5-diethylbarbituric acid) and 5,5-diethylhydantoin were investigated in the male F344/NCr rat. Steady-state total (free plus
Lana X Garmire et al.
Pharmaceutical research, 24(12), 2171-2186 (2007-08-19)
Validate and exemplify a discrete, componentized, in silico, transwell device (ISTD) capable of mimicking the in vitro passive transport properties of compounds through cell monolayers. Verify its use for studying drug-drug interactions. We used the synthetic modeling method. Specialized software
H Y Yang et al.
Molecular pharmacology, 46(5), 922-928 (1994-11-01)
Expression of functional cytochrome P450 (CYP) isoforms in human embryonic tissues was explored during organogenesis (days 50-60 of gestation) with substrate probes, inhibitor probes, and immunoprobes and by reverse transcription-polymerase chain reaction (PCR), cloning, and sequencing. Evidence was obtained for
Y Lin et al.
Drug metabolism and disposition: the biological fate of chemicals, 29(4 Pt 1), 368-374 (2001-03-22)
Most cytochrome P450 (P450 or CYP)-catalyzed reactions are adequately described by classical Michaelis-Menten kinetic parameters (e.g., Km and Vmax), which are usually determined by a saturation profile of velocity of product formation versus substrate concentration. In turn, these parameters may
查看所有相關論文

文章

Phase I Drug Metabolism

Phase I biotransformation reactions introduce or expose functional groups on the drug with the goal of increasing the polarity of the compound. Although Phase I drug metabolism occurs in most tissues, the primary and first pass site of metabolism occurs during hepatic circulation.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務